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Semaphorins are mainly known as guidance signals in development, acting through receptors called Plexins.
However, their role in cancer is rapidly emerging in the regulation of tumor angiogenesis, tumor growth, cancer
cell invasiveness, andmetastatic spreading. Intriguingly, activated plexins can transactivate receptor tyrosine
kinases, suchasMET,VEGFR2,FGFR2,andERBB2,and lead todistinctiveeffects inacell-context-dependent
manner. Moreover, certain semaphorins concomitantly target endothelial and cancer cells, and can achieve
remarkable inhibition of angiogenesis and tumor growth, associated with anti-metastatic activity. Altogether,
these data validate the identification of semaphorin signals as promising therapeutic targets in cancer.Introduction
Semaphorins
There are around 20 semaphorin genes in vertebrates that can
be subdivided intomultiple subclasses based on common struc-
tural features (Kolodkin et al., 1993; Semaphorin Nomenclature
Committee, 1999). Members of subclass 3 are secreted, while
the others are membrane-bound and, under certain circum-
stances, can be shed upon cleavage. All semaphorins have in
common a sema domain, characterized by a seven-blade beta
propeller structure, which contains sites for semaphorin dimer-
ization and receptor binding (Liu et al., 2010; Nogi et al., 2010;
Janssen et al., 2010).
Semaphorin Receptors
Main receptors for semaphorins are the plexins, a family com-
prising nine members in vertebrates (reviewed by Tamagnone
and Comoglio, 2000). The extracellular domain of plexins also
includes a sema domain that is putatively involved in ligand
binding. A subset of the secreted semaphorins cannot interact
with plexins alone, but require the presence of obligate corecep-
tor molecules called neuropilins (Nrp1/Nrp2) (Tamagnone et al.,
1999; Takahashi et al., 1999), providing additional binding sites
for ligands (see Figure 1) (for general reviews, see Kruger et al.,
2005; Zhou et al., 2008; Neufeld and Kessler, 2008). Notably,
neuropilins are also well-known coreceptors for vascular endo-
thelial growth factors (VEGFs).
Semaphorin Signaling
Plexins are responsible for most known intracellular pathways
triggered by semaphorins, while the short cytoplasmic tail of
neuropilins is apparently devoid of signaling functions. The
intracellular domain of plexins is largely conserved in the
family and carries an unconventional split domain with
GTPase-activating protein (GAP) activity for R-Ras, M-Ras,
and Rap (Oinuma et al., 2004; Wang et al., 2012). Moreover,
the cytoplasmic domain of different plexins was found to asso-
ciate with other putative effector proteins, such as p190Rho-
GAP, PDZ-RhoGEFs, MICALs, FARP2 (reviewed by Zhou
et al., 2008), and 14.3.3 proteins (Yang and Terman, 2012).Typical outcomes of plexin activation are inhibition of integrin-
mediated cell-substrate adhesion and cytoskeletal remodeling.
In experimental models, this leads to retraction of pseudopodia,
and eventually to cell rounding, or to the typical ‘‘collapse’’ of
axonal growth cone processes. In physiology, these mecha-
nisms are thought to mediate semaphorin-dependent guidance
of axonal extension and directional cell migration (Tran et al.,
2007). Notably, semaphorin and plexinmouse knock-out models
display defects in axon guidance, cardiovascular development
(sometimes lethal), bone homeostasis, and immune response.
Additional Interactors and Signaling Pathways
Certain semaphorins were found to interact with additional mole-
cules on the cell surface beyond their plexin receptors (see
Figure 1), thereby mediating alternative signaling pathways in
specific cellular settings. For instance, in lymphocytes, Sema-
phorin4D (Sema4D) can bind CD72 (Kumanogoh et al., 2000),
and Sema4A the membrane receptor Tim-2 (Kumanogoh et al.,
2002). Sema7A can engage integrin-beta1 through an RGDmotif
included in its amino acid sequence and trigger Focal Adhesion
Kinase-dependent pathway (Pasterkamp et al., 2003). More-
over, other signaling receptors have been found in association
with plexins and neuropilins on the cell surface; these include
the adhesion molecule L1-CAM (Castellani et al., 2002) and
the receptor tyrosine kinases (RTKs) OTK/PTK7, MET, RON,
VEGFR2, and ERBB2 (reviewed by Franco and Tamagnone,
2008). In particular, it was shown that semaphorins can trans-
activate plexin-associated RTKs and promote cell growth and
invasion, as opposed to the usual pathways leading to inhibition
of migration. Thus, semaphorins can trigger multiple signaling
cascades and often distinctive functions in a cell-context-
dependent manner.
Semaphorins Are Versatile and Multifaceted Regulatory
Signals in the Tumor Context
Accumulating evidence indicates that semaphorin signals can
play a major role in the tumor context, beyond their established
role in development (reviewed by Capparuccia and Tamagnone,Cancer Cell 22, August 14, 2012 ª2012 Elsevier Inc. 145
Figure 1. Schematic Representation of Main Semaphorin-Plexin
Interactions
Plexins and plexin-associated molecules are indicated in ovals, while other
putative semaphorin receptors are shown in green boxes.
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their receptors, and experimental data show that these signals
can either promote, or inhibit, tumor cell migration, growth,
and survival. Thereby, semaphorin functions in the tumor context
may be partly due to a direct (‘‘autocrine’’ or paracrine) regulation
of cancer cells; a few specific examples will be discussed in this
review. Notably, the expression of semaphorins and their recep-
tors in tumors has been found up- or downregulated compared
to normal tissues. The molecular mechanisms responsible for
this regulation are largely unknown, but certain transcription
factors and miRNAs have been implicated (e.g., Clarhaut et al.,
2009; Coma et al., 2011; Urbich et al., 2012). On the other
hand, mutations or other alterations of semaphorin or sema-
phorin receptor genes are rarely seen in human tumors (Balak-
rishnan et al., 2009), with the exception of PlexinB1 mutations
reported in prostate cancer (Wong et al., 2007).
In addition to cancer cells, semaphorins and their receptors
are expressed in normal cells of the tumor microenvironment.
In particular, several semaphorins have been found to regulate
endothelial cell function, either as inhibitors or promoters of
angiogenesis (reviewed by Neufeld et al., 2012), and a number
of them were recently shown to control tumor vasculature
(diffusely discussed below). Certain semaphorins are further-
more importantly involved in the regulation of immune response
(for a review see Takamatsu and Kumanogoh, 2012). For in-
stance, Sema4D signaling was found to promote B lymphocyte
activation, while Sema4A and Sema6D were implicated in T
lymphocytes function. In one study, Sema3A promoted the
cytokine storm induced by inflammatory signals (Wen et al.,
2010), whereas others reported that Sema3A signaling inhibits
T-cell function (Catalano et al., 2006; Lepelletier et al., 2006;
Yamamoto et al., 2008). A recent report indicated that Sema4A
is a chemoattractant for monocyte-macrophages (Meda et al.,
2012); in addition, both Sema4A and Sema7A were found to
induce monocytes to release pro-inflammatory and pro-angio-
genic molecules (Meda et al., 2012; Holmes et al., 2002; Suzuki
et al., 2007). Thus, specific semaphorins could have a role in
controlling the recruitment of leucocytes into the tumor microen-
vironment, and their immuno-modulatory activity could have an
impact on tumor progression; however, these potential functions
have not been carefully investigated as yet.146 Cancer Cell 22, August 14, 2012 ª2012 Elsevier Inc.A further semaphorin function potentially relevant to cancer
is linked to their emerging role in bone homeostasis. In fact,
signaling cascades triggered by Sema6D/PlexinA1, Sema4D/
PlexinB1, and Sema3A/Nrp1 have been shown to play a crucial
role in the regulation of osteoclast and osteoblast differentiation
and the balance between osteolysis and osteodeposition (Take-
gahara et al., 2006; Negishi-Koga et al., 2011; Hayashi et al.,
2012). As tumor cells can release all of the above signals within
the tumor microenvironment, this could be relevant with respect
to the development of bone metastatic sites.
Due to their versatile activity and wide receptor distribution in
different cell types, semaphorin signals couldmediate an intense
cross-talk between cancer cells and the microenvironment, and
play multiple concomitant functions potentially relevant to tumor
progression. This complex scenario has been investigated for
few family members by experiments in vivo, in mouse models.
This review will mainly focus on recent studies that highlighted
certain semaphorin signaling pathways as major modifiers of
cancer progression and potential therapeutic targets relevant
in translational perspective.
Semaphorins Are Potent Regulators of Tumor
Angiogenesis In Vivo
Growing tumors can release strong and diverse pro-angiogenic
stimuli and usually they become dependent on angiogenesis for
growth and survival; this explains why anti-VEGF drugs, for
example, can dramatically induce tumor shrinkage. However,
refractoriness to drugs blocking individual pro-angiogenic fac-
tors may eventually arise due to the increased production of
alternative signals sustaining tumor vessel development (Carme-
liet and Jain, 2011). A further worrying aspect of VEGF-targeted
drugs is the reported risk of inducing tumor invasion and meta-
static spreading. Although the mechanisms underlying this pro-
cess are still controversial, this seems to involve hypoxia-driven
induction of tumor invasiveness (Semenza, 2012), and it is pres-
ently addressed by combined treatment with drugs directly tar-
geting cancer cells.
Multiple semaphorins have been associated with the regula-
tion of tumor vasculature, including Sema3A, Sema3E, Sema3F,
and Sema3G (as inhibitory signals); Sema4D (as pro-angiogenic
factor); and others (reviewed by Neufeld et al., 2012). These
semaphorins may be released by cancer cells, as well as
by stromal cells in the tumor microenvironment. Furthermore,
endothelial cells themselves produce semaphorins controlling
angiogenesis in autocrine manner. Importantly, the expression
of certain semaphorins (and receptors) seems to be regulated
in response to tissue hypoxia, including upon the ‘‘angiogenic
switch’’ of growing tumors, as part of a balanced set of antago-
nistic signals controlling the development of new vessels (Coma
et al., 2011; Moriya et al., 2010; Sun et al., 2009; Maione et al.,
2009). However, this physiologic function of semaphorins seems
to be distorted in cancer progression. For instance, the levels
of anti-angiogenic factors Sema3A and Sema3F are often down-
regulated in advanced tumors (Maione et al., 2009; Bielenberg
et al., 2004), while the pro-angiogenic Sema4D is typically in-
creased (Basile et al., 2006). It was furthermore reported that
Sema4D levels are induced by VEGF and inflammatory cytokines
(Smith et al., 2011). Notably, in addition to being produced
by cancer cells, Sema4D may be released into the tumor
Figure 2. Semaphorins: A Novel Type of Anti-Angiogenic Factors Inhibiting Cancer Progression
(A) Unlike in normal tissues, the balanced activity of antagonistic signals controlling new vessel development is often distorted in tumors, which are characterized
by predominance of pro-angiogenic signals (including VEGF, Sema4D, and others).
(B) Upon treatment with drugs blocking pro-angiogenic factors, tumors undergo hypoxia and shrinkage; but eventually they may become resistant by exploiting
alternative pro-angiogenic signals. Moreover, tumor hypoxia may induce cancer cell invasiveness and metastatic spreading.
(C) Anti-angiogenic molecules directly targeting endothelial cells (such as Sema3A or Uncl-Sema3E) may be able to overcome these problems. Moreover, by
directly inhibiting tumor cell invasiveness (with Sema3A, Uncl-Sema3E, but also anti-PlexinB1 antibodies), the metastatic spreading associated with tumor
hypoxia could be prevented.
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macrophages (Sierra et al., 2008) and, potentially, platelets
(Zhu et al., 2007). Although genetic deletion in mice demon-
strated that Sema4D is not required for developmental angio-
genesis, experiments in vivo indicated that this semaphorin
has a strong pro-angiogenic activity in tumor models (Sierra
et al., 2008). While Sema4D loss or functional blockade in the
microenviroment inhibited tumor growth and progression, this
effect does not seem to rely exclusively on the main Sema4D-
receptor PlexinB1, potentially implicating the alternative homo-
log PlexinB2 (Fazzari et al., 2007). Notably, Sema4D can control
cancer cells in addition to tumor vasculature (discussed below),
sustaining invasion and metastasis.
As an alternative to blocking the activity of pro-angiogenic
factors, the direct targeting of endothelial cells by treatment
with inhibitory semaphorins was assayed in preclinical tumor
models in mice (see Figure 2). Sema3F was in fact the first sem-
aphorin shown to have an anti-angiogenic activity in tumor
models in mice (Bielenberg et al., 2004; Kessler et al., 2004).Sema3F binds to the coreceptor molecule Neuropilin-2 (Nrp2),
which—in addition to interacting with plexins—is typically found
in endothelial and lympho-endothelial cells in association with
VEGFR2 and VEGFR3 (Ka¨rpa¨nen et al., 2006; Caunt et al.,
2008). Intriguingly, derivatives of neural crest cells, including
melanoma, also express Nrp2; and the forced overexpression
of Sema3F in melanoma cells transplanted in mice blocked
tumor angiogenesis, tumor growth, and metastatic spreading
(Bielenberg et al., 2004). These data demonstrated that Sema3F
is capable of inhibiting tumor angiogenesis and lympho-angio-
genesis in vivo, and suggested that it may regulate a subset of
cancer cells via Nrp2. Later studies have reported Nrp2 overex-
pression in human tumors (e.g., Dallas et al., 2008) and linked it
with cancer progression; however, the implicated signaling path-
ways have not been clearly elucidated and they might reflect
semaphorin-independent functions.
Recent reports highlighted other semaphorin molecules that
potently inhibit tumor angiogenesis in vivo, independent of
VEGF blockade, and concomitantly control invasive/metastaticCancer Cell 22, August 14, 2012 ª2012 Elsevier Inc. 147
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inhibit endothelial cells (Miao et al., 1999). This was initially asso-
ciated with the fact that Sema3A coreceptor Neuropilin-1 (Nrp1)
also binds VEGF and mediates its pro-angiogenic activity. It was
later shown that Sema3A- and VEGF-binding sites on Nrp1 are
largely independent (Appleton et al., 2007); moreover, the antag-
onistic activity of these signals in endothelial cells seems to
implicate distinct signaling pathways, rather than binding com-
petition to Nrp1. Sema3A-receptor complexes are thought to
include plexins of A-subfamily, beyondNrp1, especially PlexinA4
and/or PlexinA1. Notably, a recent report (discussed below) sug-
gests that these plexins may play a role in the regulation of both
endothelial and cancer cells (Kigel et al., 2011). Sema3A was
found to inhibit integrin-mediated adhesion to the extracellular
matrix, which is crucially required for endothelial cell migration
and survival (Serini et al., 2003; Casazza et al., 2011). Upon
delivery in different preclinical tumor models in mice, Sema3A
displayed a strong anti-angiogenic effect associated with inhibi-
tion of cancer cell motility and metastatic spreading in different
tumor models (Maione et al., 2009, 2012; Casazza et al., 2011;
Chakraborty et al., 2012). According to one study, the treatment
with Sema3A can achieve ‘‘normalization’’ of the tumor vascula-
ture in spontaneous tumor models in mice, possibly by pruning
aberrant tumor vessels (Maione et al., 2009). In another study,
the sustained treatment with Sema3A resulted in extensive
vessel disruption and hypoxia in transplanted tumors (Casazza
et al., 2011), suggesting that vessel normalization may be ob-
tained in a specific therapeutic window. Moreover, Sema3A
directly inhibited cancer cell invasiveness dependent on Nrp1
expression (Casazza et al., 2011). Importantly, Nrp1 levels are
typically higher in tumors compared to respective normal tis-
sues, and Nrp1 expression seems to confer a selective advan-
tage in tumor progression (reviewed by (Rizzolio and Tamag-
none, 2011), which may implicate fewer risks of developing
resistance to Sema3A-mediated inhibition. Of note, combined
treatment with Sema3A could prevent the metastatic spreading
induced by VEGF-blocking drugs in a spontaneous tumor model
in mice (Maione et al., 2012).
Another secreted semaphorin found to inhibit tumor angiogen-
esis is Sema3E. The role of Sema3E in developmental angiogen-
esis is well established, even if multiple signaling cascades have
been implicated (reviewed by Tamagnone and Mazzone, 2011).
Importantly, Sema3E signaling in endothelial cells does not
require neuropilins, but rather depends on the specific receptor
PlexinD1 (Gu et al., 2005). PlexinD1 is expressed at high levels in
developing vessels, especially in the endothelial ‘‘tip’’ cells that
lead vascular sprouts. In the adult, PlexinD1 expression is mainly
found in sites of neo-angiogenesis, including tissues recover-
ing from ischemic insults, and growing tumors (Roodink et al.,
2005; Moriya et al., 2010; Fukushima et al., 2011). Intriguingly,
Sema3E-PlexinD1 signaling was found to trigger VEGFR2 acti-
vation in certain neurons (Bellon et al., 2010). Instead, PlexinD1
activation in endothelial cells inhibits their migration and restricts
sprouting angiogenesis, antagonizing pro-angiogenic signals; in
fact, during development, Sema3E is strictly localized in order to
define permissive and non-permissive areas for vascularization
(Gu et al., 2005). Recent studies implicated ARF6 activation by
PlexinD1 in the negative regulation of integrin function mediated
by Sema3E in endothelial cells (Sakurai et al., 2010, 2011).148 Cancer Cell 22, August 14, 2012 ª2012 Elsevier Inc.Notably, forced Sema3E overexpression in experimental tumor
models resulted in a dramatic anti-angiogenic effect, associated
with strong suppression of tumor growth (Casazza et al., 2010).
Sema3E Is a Dual-Activity Factor Independently
Controlling Endothelial and Cancer Cells
Importantly, in addition to inhibiting endothelial cells, Sema3E
was found to control the behavior of cancer cells through an
independent signaling cascade. In fact, this secreted sema-
phorin is proteolytically converted into a fragment, known as
p61-Sema3E, which plays a distinctive autocrine function in
cancer cells by driving invasion and metastasis without sig-
nificantly impinging tumor growth (Casazza et al., 2010). This
activity is strictly dependent on the transactivation of the onco-
genic tyrosine kinase ERBB2, associated with PlexinD1, in
response to p61-Sema3E stimulation. By expression profiling
analysis, it was found that higher Sema3E expression in primary
tumors (colorectal and melanoma) correlates with increased
metastatic progression (Casazza et al., 2010). Notably, another
group reported that Sema3E-PlexinD1 signaling induces epithe-
lial-to-mesenchymal transition in ovarian endometrioid cancer
cells (Tseng et al., 2011).
In a recent study, it was shown that a mutated non-process-
able version of Sema3E (Uncl-Sema3E) is unable to elicit
ERBB2 transactivation and pro-metastatic signaling in cancer
cells (Casazza et al., 2012). Yet, Uncl-Sema3E remains fully
competent for binding PlexinD1 and triggering its inhibitory
activity in endothelial cells, which leads to decreased angiogen-
esis and tumor growth in mice. Moreover, the same molecule
‘‘competed out’’ the autocrine signaling of endogenous p61-
Sema3E in cancer cells and blocked their invasive and meta-
static behavior (Casazza et al., 2012). Uncl-Sema3E was effec-
tive in multiple tumor models in mice, including spontaneous
RipTag2 pancreatic tumors, and transplanted LLC tumors
nonresponsive to VEGF blockade. This is consistent with the
idea that these semaphorins exert a direct anti-angiogenic
activity on endothelial cells, rather than interfering with pro-
angiogenic signals (Figure 2). Moreover, a concomitant direct
inhibitory effect of Uncl-Sema3E in cancer cells was implicated
to prevent hypoxia-driven invasion and metastasis. Together
with the examples discussed in the previous section, these data
highlight the relevance of anti-angiogenic semaphorins that can
directly target endothelial cells and potently suppress tumor
growth inmousemodels without promoting cancer invasiveness,
and even concomitantly reducing metastatic spreading. An open
question concerns the possibility of developing functional anti-
bodies or small molecules, alternative to the large recombinant
semaphorin proteins tested so far in mouse models, in order
to trigger plexin-mediated inhibitory signals or block signaling
pathways elicited by endogenous semaphorins.
PlexinB1 Plays Tumor-Type-Specific Functions in
Cancer Progression
PlexinB1 is another familymember coupledwith RTKs on the cell
surface, in particular withMET (Giordano et al., 2002) and ERBB2
(Swiercz et al., 2004). These interactions have a major role in
Sema4D-PlexinB1 signaling, as they can mediate distinctive
and sometimes divergent pathways in a cell-context-dependent
manner, for instance leading to opposite regulation of RhoA
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versial literature related to the functional role of PlexinB1 in
human tumors. In fact, in addition to its pro-angiogenic activity
in endothelial cells, a number of studies reported pro-invasive
functions of Sema4D-PlexinB1 signaling in a variety of cancer
cell types (Giordano et al., 2002; Swiercz et al., 2008; Sierra
et al., 2008; Binmadi et al., 2012; Ye et al., 2010; Qiang et al.,
2011). Moreover PlexinB1 is overexpressed and frequently
mutated in prostatic cancer, and some of these genetic changes
were associated with a ‘‘switch’’ of receptor signaling accompa-
nied by increased invasiveness and metastasis (Wong et al.,
2007). On the other hand, in melanoma, oncogenic signaling
by mutated constitutively active BRAF was found instead to
suppress PlexinB1 expression (Argast et al., 2009); furthermore,
experimental evidence indicated a tumor suppressor function of
overexpressed PlexinB1 in melanoma cells (Argast et al., 2009;
Stevens et al., 2010). One group recently addressed this issue
in vivo by breeding an ERBB2-driven mouse breast carcinoma
model in a PlexinB1 null background (Worzfeld et al., 2012). It
emerged that PlexinB1 expression in vivo is not required for
tumor growth or tumor angiogenesis, consistent with previous
data, but it has a major role in promoting metastatic spreading.
The specific role of Sema4D was not elucidated in this study;
however, in vitro experiments suggested that PlexinB1 expres-
sion in cancer cells is required to mediate RhoA/RhoC activation
elicited by overexpressed and constitutively active ERBB2
kinase (Worzfeld et al., 2012). Notably, low levels of PlexinB1
in ERBB2-overexpressing human breast tumors significantly
correlated with better patient prognosis. Moreover, interfering
with PlexinB1 was proposed as complementary therapeutic
approach to block invasion and metastasis of ERBB2-positive
tumors. Beyond the analysis of gene-deficient mouse models
and RNAi approaches in vitro, this conclusion was based on
the application of PlexinB1-blocking antibodies to cultured cells
(Worzfeld et al., 2012). In fact, the use of interfering antibodies
in vivo to manipulate Sema4D/PlexinB1 function in tumors
has not been tested as yet. Interestingly, in a previous study,
co-expression of PlexinB1 and MET tyrosine kinase in human
breast and ovarian cancers was similarly found to correlate
with metastatic progression (Valente et al., 2009). On the other
hand, another group reported opposite prognostic significance
of PlexinB1 expression in a subset of patients with estrogen
receptor-positive breast cancer, indicating better survival in
PlexinB1-expressing tumors and poor prognosis upon PlexinB1
loss (Rody et al., 2009). Thus, depending on the tumor type,
PlexinB1 expression may be considered as a negative or a
positive prognostic factor. Emerging data seem to suggest
a similar scenario of tumor context-dependence for the homolo-
gous receptor PlexinB3, interacting with Sema5A (Artigiani et al.,
2004). For instance, it was reported that an increased expression
of Sema5A and PlexinB3 significantly correlates with invasion
and metastasis in human gastric and pancreatic tumors (Pan
et al., 2009; Sadanandam et al., 2010). On the other hand,
another group found that Sema5A-PlexinB3 signaling inhibits
the migration of human glioma cells and leads to inactivation of
the pro-invasive protein fascin (Li et al., 2012). Further studies
are required to elucidate whether this reflects the involvement
of distinct receptor complexes and alternative signaling path-
ways, as seen for PlexinB1.PlexinA4 Is Involved in Multiple Semaphorin Receptor
Complexes, Responsible for Different Functions in
Cancer and Endothelial Cells
In a recent study, PlexinA4 was reported to associate with
RTKs VEGFR2 and FGFR2, and thereby promote signaling path-
ways leading to increased viability of endothelial and tumor cells
(Kigel et al., 2011). Similar effects were observed upon overex-
pression of PlexinA4-ligand Sema6B, potentially suggesting
that elevated Sema6B and/or PlexinA4 levels in tumors may
correlate with progression. Intriguingly, it was proposed that
PlexinA4-RTK receptor complexes may be functionally alterna-
tive to PlexinA4-PlexinA1 heterodimers responsible for Sema3A
anti-angiogenic signals (Kigel et al., 2011). Thereby PlexinA4
might mediate opposite biological functions depending on the
implicated semaphorin ligand and plexin-associated signal
transducers. Based on these data, it could be envisaged that
cancer treatment with Sema3A (or related molecules) could
lead not only to direct inhibition of tumor cell migration and
angiogenesis, but also prevent stimulatory signaling cascades
by titrating out the bivalent receptor component PlexinA4.
Conclusions
In summary, inhibitory semaphorins that restrict cell migration
and angiogenesis during development are often downregulated
in advanced tumors, and proved to be effective tumor sup-
pressor molecules in preclinical mouse models. Other sema-
phorins and plexins, such as Sema4D, PlexinB1, Sema3E and
PlexinD1, are frequently upregulated in tumors as they support
cancer progression and metastatic spreading. They have been
proposed as prognostic predictors and recombinant molecular
tools capable of blocking these pathways and effectively
reducing tumor angiogenesis and metastatic spreading in
preclinical trials in mice. Because the network of semaphorin
signals is rather complex and cell-context-dependent, further
studies may help to establish the relevance of individual family
members as prognostic predictors and therapeutic targets for
specific tumor types in humans. Moreover, biotechnological
studies will aid in the development of improved molecular tools
interfering with plexin activation and applicable for use in clinical
trials.
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